Theralase TechnologiesTLTFF +1.22%46 Quick Ratio is 1.11 as of Mar. 2026, which is 50% below its 10-year median of 2.23. GuruFocus rates TLTFF with a GF Score™ of 46/100 and a GF Value™ of $0.13 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Theralase Technologies ranks worse than 72.83% on this metric.
Theralase Technologies has a quick ratio of 1.11. It generally indicates good short-term financial strength.
The historical rank and industry rank for Theralase Technologies's Quick Ratio or its related term are showing as below:
TLTFF'
s Quick Ratio Range Over the Past 10 Years
Min: 0.52 Med: 2.23 Max: 18.59
Current: 1.11
During the past 13 years, Theralase Technologies's highest Quick Ratio was 18.59. The lowest was 0.52. And the median was 2.23.
TLTFF's Quick Ratio is ranked worse than 72.83% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 1.865
vs TLTFF: 1.11
Theralase Technologies (OTCPK:TLTFF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Theralase Technologies Quick Ratio Related Terms
Theralase Technologies Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Theralase Technologies's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Theralase Technologies's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies (TLTFF) has a Quick Ratio of 1.11 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Theralase Technologies and its competitors. This is 50% below median its historical median of 2.23. Over the past decade, Theralase Technologies' Quick Ratio has ranged from 0.52 to 18.59. According to the industry distribution chart, Theralase Technologies ranks #622 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 72.8%.
Is Theralase Technologies' Quick Ratio too high?
Theralase Technologies' current Quick Ratio of 1.11 is 50% below median its 10-year median of 2.23. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 18.59. The Medical Devices & Instruments industry median Quick Ratio is 1.87. Theralase Technologies' value of 1.11 is 40.5% below this industry median. Based on the distribution chart, Theralase Technologies ranks #622 out of 854 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Theralase Technologies has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Quick Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #622 out of 854 companies for Quick Ratio. This places Theralase Technologies in the lower half of its industry. The industry median Quick Ratio is 1.87. Theralase Technologies' value of 1.11 is 40.5% below this benchmark. Historically, Theralase Technologies' own Quick Ratio has ranged from 0.52 to 18.59 over the past decade. While the company's 10-year median is 2.23 vs. the industry median of 1.87, Theralase Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.87, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theralase Technologies's current Quick Ratio of 1.11 is 40.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Theralase Technologies and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theralase Technologies's current Quick Ratio is 1.11, which is 50% below median its own 10-year median of 2.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.17 — trading 28.1% above its estimated fair value. The current Quick Ratio is 1.11, which is 50% below median its 10-year median of 2.23 and 40.5% below the Medical Devices & Instruments industry median of 1.87. Theralase Technologies' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current Quick Ratio is 1.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TLTFF) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of $0.17 is trading 28.1% above its estimated GF Value™ of $0.13.
GuruFocus considers Theralase Technologies to be Modestly Overvalued.
Key valuation signals for TLTFF:
Quick Ratio: 1.11 (50% below median its 10-year median of 2.23)
GF Value™: $0.13 vs. price of $0.17 (28.1% above fair value)
Industry Position: 40.5% below the Medical Devices & Instruments median (#622 of 854)
No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
46GF Score
Get the complete analysis for TLTFF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLTFF has been successfully added to your 
